Updated on 4 January 2013
Good news for symptomatic vitreomacular adhesion (VMA) patients - ThromboGenics to launch intravitreal proteolytic enzyme injection, Jetrea (ocriplasmin)
Singapore: ThromboGenics, an integrated Belgium biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, will launch Jetrea (ocriplasmin) intra-vitreal injection on January 14th, 2013.
Jetrea (ocriplasmin) intra-vitreal injection is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion (VMA). The US price for a single-use glass vial of Jetrea is set at $3,950.
Jetrea represents a paradigm shift and offers a pharmacological treatment option to patients suffering with symptomatic VMA. The US FDA approved the drug in October 2012 as the first pharmacological agent for the treatment of symptomatic VMA.
Symptomatic VMA is a progressive, sight-threatening condition that, which when left untreated, frequently leads to retinal distortion, further deterioration in vision, and irreversible damage to eyesight. The recommended dose of Jetrea is 0.125 mg (0.1 mL) of the diluted solution administered by intra-vitreal injection to the affected eye once as a single injection.